Modality
Radioligand
MOA
MALT1i
Target
LAG-3
Pathway
Fibrosis
MCLCSU
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Apr 2027
Phase 2Current
NCT06305441
1,116 pts·MCL
2018-10→2026-01·Not yet recruiting
NCT07257385
1,453 pts·CSU
2018-02→2027-04·Terminated
2,569 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-212mo agoPh3 Readout· MCL
2027-04-281.1y awayPh3 Readout· CSU
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-01-21 · 2mo ago
MCL
Ph3 Readout
2027-04-28 · 1.1y away
CSU
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06305441 | Phase 2/3 | MCL | Not yet recr... | 1116 | Safety |
| NCT07257385 | Phase 2/3 | CSU | Terminated | 1453 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |